Evaluation of Thoracic Tumors With 18F-FMT and 18F-FDG PET-CT A Clinicopathological Study
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Registration Number
- NCT00698373
- Lead Sponsor
- Gunma University
- Brief Summary
L-\[3-18F\]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for positron emission tomography (PET). The aim of this study was to determine whether PET-CT with 18F-FMT provides additional information for the preoperative diagnostic workup as compared with 18F-FDG PET. Tumor uptake of 18F-FMT was compared with several immunohistochemical markers including L-type amino acid transporter 1 (LAT1).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Patients with indeterminate pulmonary nodule suspicious of lung cancer
Exclusion Criteria
- Patients with other malignancies and those who had received cancer treatment within the past 5 years were excluded.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the role of L-type amino acid transporter 1 (LAT1) in 18F-FMT uptake for non-small cell lung cancer diagnosis?
How does 18F-FMT PET-CT compare to 18F-FDG PET-CT in detecting molecular subtypes of thoracic tumors?
What clinicopathological correlations were found between 18F-FMT imaging and tumor biomarkers in non-small cell lung cancer?
Are there specific adverse events associated with 18F-FMT PET-CT imaging in thoracic tumor patients?
What are the potential applications of 18F-FMT in combination with other imaging agents for thoracic tumor staging?